JPRN-jRCT2080225114已完成1 期
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors
ovartis Pharma. K.K.0 个研究点目标入组 145 人开始时间: 2020年3月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 145
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with metastatic and/or advanced malignancies not amenable to curative treatment by surgery.
- •- Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening and during the study.
- •- ECOG Performance Status of <2.
排除标准
- •- Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require concurrent treatment - including surgery, radiation and/or corticosteroids.
- •- History of severe hypersensitivity reaction to any ingredient of study drug(s) and other mAbs and/or their excipients.
- •- Impaired cardiac function HIV Known history of tuberculosis Systemic chronic steroid therapy
- •- Other protocol-defined inclusion/exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations - DKN-01 inhibition in advanced liver cancerMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatocellular CarcinomaEUCTR2017-002468-41-DEniversity Medical Center of the Johannes Gutenberg- University Mainz70
进行中（未招募）
不适用
A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC) - N/AEUCTR2007-004391-39-NLovartis Pharma Services AG104
进行中（未招募）
不适用
A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC)advanced or metastatic renal cell carcinomaMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2007-004391-39-FRovartis Pharma Services AG81
进行中（未招募）
不适用
Efficacy and safety of TKI258 in kidney canceradvanced or metastatic renal cell carcinomaMedDRA version: 13.1Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-004391-39-DEovartis Pharma Services110
已完成
1 期
ovartis sponsored Phase 1 studyJPRN-jRCT2080223249ovartis Pharma. K.K.17